|
|
|
Volumn 151, Issue 10, 2012, Pages
|
|
[Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
DACARBAZINE;
IPILIMUMAB;
MONOCLONAL ANTIBODY;
AUTOIMMUNITY;
CYTOTOXIC T LYMPHOCYTE;
DRUG ANTAGONISM;
DRUG APPROVAL;
DRUG EFFECT;
DRUG MONITORING;
DRUG SURVEILLANCE PROGRAM;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
MELANOMA;
METHODOLOGY;
PATHOLOGY;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PROPORTIONAL HAZARDS MODEL;
REVIEW;
SKIN TUMOR;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AUTOIMMUNITY;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
CTLA-4 ANTIGEN;
DACARBAZINE;
DRUG APPROVAL;
DRUG MONITORING;
HUMANS;
IMMUNOTHERAPY;
MELANOMA;
PHARMACOVIGILANCE;
PROPORTIONAL HAZARDS MODELS;
SKIN NEOPLASMS;
T-LYMPHOCYTES, CYTOTOXIC;
TREATMENT OUTCOME;
|
|
EID: 84873708258
PISSN: 00177768
EISSN: None
Source Type: None
DOI: None Document Type: Review |
|
Times cited : (2)
|
|
References (0)
|
